These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 23072796)

  • 1. The rationale of pharmacoeconomic analysis in rheumatologic indications.
    Turchetti G; Scalone L; Della Casa Alberighi O; Mosca M; Montella S; Cortesi PA; Mantovani LG
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S64-71. PubMed ID: 23072796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interest of modelling in rheumatoid arthritis.
    Beresniak A; Dupont DM; Becker JC; Merkesdal S
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S96-101. PubMed ID: 23078913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis.
    Furneri G; Mantovani LG; Belisari A; Mosca M; Cristiani M; Bellelli S; Cortesi PA; Turchetti G
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S72-84. PubMed ID: 23072761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomics of drug therapy for rheumatoid arthritis.
    Tugwell P
    Rheumatology (Oxford); 2000 Jun; 39 Suppl 1():43-7. PubMed ID: 11001379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-rheumatoid biologics and pharmacoeconomic evaluation].
    Tsutani K; Igarashi A
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():711-8. PubMed ID: 15799447
    [No Abstract]   [Full Text] [Related]  

  • 6. Health economics: implications for novel antirheumatic therapies.
    Kavanaugh A
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv65-9. PubMed ID: 16239392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic issues with new rheumatologic therapeutics.
    Kavanaugh A
    Curr Opin Rheumatol; 2007 May; 19(3):272-6. PubMed ID: 17414954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues.
    Lapadula G; Ferraccioli GF
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S102-6. PubMed ID: 23078880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis.
    Her M; Kavanaugh A
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S107-11. PubMed ID: 23078839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacoeconomic evaluation for the treatment of rheumatoid arthritis].
    Liu B; Zeng XX
    Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(11):841-4. PubMed ID: 23859391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treat-to-target in rheumatoid arthritis: clinical and pharmacoeconomic considerations. Introduction.
    Turchetti G; Smolen JS; Kavanaugh A; Braun J; Pincus T; Bombardieri S
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S1. PubMed ID: 23168235
    [No Abstract]   [Full Text] [Related]  

  • 13. The pharmacoeconomics of newer therapeutics for rheumatic diseases.
    Kavanaugh A
    Rheum Dis Clin North Am; 2006 Feb; 32(1):45-56, viii. PubMed ID: 16504820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomics: friend or foe?
    Drummond M
    Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii44-7. PubMed ID: 17038472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?
    Modena V; Bianchi G; Roccatello D
    Autoimmun Rev; 2013 Jun; 12(8):835-8. PubMed ID: 23219766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies.
    Borrás-Blasco J; Navarro Ruiz A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):71-9. PubMed ID: 25555555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?
    Kavanaugh A
    Nat Clin Pract Rheumatol; 2006 Jul; 2(7):346-7. PubMed ID: 16932716
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Maetzel A; Strand V; Tugwell P; Wells G; Bombardier C
    Arthritis Rheum; 2002 Dec; 47(6):655-61. PubMed ID: 12522841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economics of treatment in early rheumatoid arthritis.
    Bansback N; Marra CA; Finckh A; Anis A
    Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):83-92. PubMed ID: 19233048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.